IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

Cytokine-like Activity of Liver Type Fatty Acid Binding Protein (L-FABP) Inducing Inflammatory Cytokine Interleukin-6

  • Hyunwoo Kim (Division of Nephrology, Department of Internal Medicine, Jeju National University School of Medicine) ;
  • Gaae Gil (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) ;
  • Siyoung Lee (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) ;
  • Areum Kwak (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) ;
  • Seunghyun Jo (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) ;
  • Ensom Kim (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) ;
  • Tam T. Nguyen (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) ;
  • Sinae Kim (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) ;
  • Hyunjhung Jhun (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) ;
  • Somi Kim (Division of Nephrology, Department of Internal Medicine, Jeju National University School of Medicine) ;
  • Miyeon Kim (Division of Nephrology, Department of Internal Medicine, Jeju National University School of Medicine) ;
  • Youngmin Lee (Department of Medicine, Pusan Paik Hospital, College of Medicine, Inje University) ;
  • Soohyun Kim (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University)
  • Received : 2016.09.06
  • Accepted : 2016.10.16
  • Published : 2016.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

It has been reported that fatty acid binding proteins (FABPs) do not act only as intracellular mediators of lipid responses but also have extracellular functions. This study aimed to investigate whether extracellular liver type (L)-FABP has a biological activity and to determined serum L-FABP levels in patients with end-stage renal disease (ESRD). We isolated L-FABP complementary deoxyribonucleic acid (cDNA) from the Huh7 human hepatocarcinoma cell line and expressed the recombinant L-FABP protein in Escherichia coli. A549 lung carcinoma and THP-1 monocytic cells were stimulated with the human recombinant L-FABP. Human whole blood cells were also treated with the human recombinant L-FABP or interleukin (IL)-1α. IL-6 levels were measured in cell culture supernatants using IL-6 enzyme-linked immunosorbent assay (ELISA). Human recombinant L-FABP induced IL-6 in a dose-dependent manner in A549, THP-1 cells, and whole blood cells. The blood samples of healthy volunteers and patients with ESRD were taken after an overnight fast. The serum levels of L-FABP in healthy volunteers and ESRD patients were quantified with L-FABP ELISA. The values of L-FABP in patients with ESRD were significantly lower than those in the control group. Our results demonstrated the biological activity of L-FABP in human cells suggesting L-FABP can be a mediator of inflammation.

Keywords

Acknowledgement

This work was supported by the National Research Foundation of Korea (NRF- 2015R1A2A2A01003472, -2014M3A6A4075058, -2015R1A2A1A15051472) and this paper resulted from the Konkuk University research support program. This work was done while the first author's his research year of Jeju National University in 2015. This paper was written as part of Konkuk University's research support program for its faculty on sabbatical leave in 2014.

References

  1. Furuhashi, M., and G. S. Hotamisligil. 2008. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 7: 489-503.
  2. Atshaves, B. P., G. G. Martin, H. A. Hostetler, A. L. McIntosh, A. B. Kier, and F. Schroeder. 2010. Liver fatty acid-binding protein and obesity. J. Nutr. Biochem. 21: 1015-1032.
  3. Kanda, T., H. Fujii, T. Tani, H. Murakami, T. Suda, Y. Sakai, T. Ono, and K. Hatakeyama. 1996. Intestinal fatty acid-binding protein is a useful diagnostic marker for mesenteric infarction in humans. Gastroenterology 110: 339-343.
  4. Piumngam, P., C. Schachtrup, Y. Owada, H. Kondo, C. Promptmas, and F. Spener. 2005. Expression of liver-type fatty acid-binding protein in murine lung and its release into serum upon challenge of lung with lipopolysaccharide. Eur. J. Lipid Sci. Technol. 107: 145-152.
  5. Pelsers, M. M., A. Morovat, G. J. Alexander, W. T. Hermens, A. K. Trull, and J. F. Glatz. 2002. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin. Chem. 48: 2055-2057.
  6. Monbaliu, D., V. B. de, T. Crabbe, H. E. van, C. Verwaest, T. Roskams, J. Fevery, J. Pirenne, and W. A. Buurman. 2005. Liver fatty acid-binding protein: an early and sensitive plasma marker of hepatocellular damage and a reliable predictor of graft viability after liver transplantation from non-heart-beating donors. Transplant. Proc. 37: 413-416.
  7. Akbal, E., S. Koklu, E. Kocak, B. Cakal, F. Gunes, O. Basar, Y. Tuna, and M. Senes. 2013. Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection. Arch. Med. Res. 44: 34-38.
  8. Morrissey, P. E., G. Gollin, and W. H. Marks. 1996. Small bowel allograft rejection detected by serum intestinal fatty acid-binding protein is reversible. Transplantation 61: 1451-1455.
  9. Pelsers, M. M., Z. Namiot, W. Kisielewski, A. Namiot, M. Januszkiewicz, W. T. Hermens, and J. F. Glatz. 2003. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin. Biochem. 36: 529-535.
  10. Okamoto, F., K. Sohmiya, Y. Ohkaru, K. Kawamura, K. Asayama, H. Kimura, S. Nishimura, H. Ishii, N. Sunahara, and T. Tanaka. 2000. Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin. Chem. Lab. Med. 38: 231-238.
  11. Setsuta, K., Y. Seino, T. Ogawa, M. Arao, Y. Miyatake, and T. Takano. 2002. Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am. J. Med. 113: 717-722.
  12. Pelsers, M. M., T. Hanhoff, d. Van, V, B. Arts, M. Peters, R. Ponds, A. Honig, W. Rudzinski, F. Spener, K. de, Jr., A. Twijnstra, W. T. Hermens, P. P. Menheere, and J. F. Glatz. 2004. Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin. Chem. 50: 1568-1575.
  13. Foucaud, L., J. Grillasca, I. Niot, N. Domingo, H. Lafont, R. Planells, and P. Besnard. 1999. Output of liver fatty acid-binding protein (L-FABP) in bile. Biochim. Biophys. Acta 1436: 593-599.
  14. Specht, B., N. Bartetzko, C. Hohoff, H. Kuhl, R. Franke, T. Borchers, and F. Spener. 1996. Mammary derived growth inhibitor is not a distinct protein but a mix of heart-type and adipocyte-type fatty acid-binding protein. J. Biol. Chem. 271: 19943-19949.
  15. Bronsky, J., M. Karpisek, E. Bronska, M. Pechova, B. Jancikova, H. Kotolova, D. Stejskal, R. Prusa, and J. Nevoral. 2006. Adiponectin, adipocyte fatty acid binding protein, and epidermal fatty acid binding protein: proteins newly identified in human breast milk. Clin. Chem. 52: 1763-1770.
  16. Xu, A., Y. Wang, J. Y. Xu, D. Stejskal, S. Tam, J. Zhang, N. M. Wat, W. K. Wong, and K. S. Lam. 2006. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 52: 405-413.
  17. Mita, T., M. Furuhashi, S. Hiramitsu, J. Ishii, K. Hoshina, S. Ishimura, T. Fuseya, Y. Watanabe, M. Tanaka, K. Ohno, H. Akasaka, H. Ohnishi, H. Yoshida, S. Saitoh, K. Shimamoto, and T. Miura. 2015. FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity (Silver.Spring) 23: 359-367.
  18. Lamounier-Zepter, V., C. Look, J. Alvarez, T. Christ, U. Ravens, W. H. Schunck, M. Ehrhart-Bornstein, S. R. Bornstein, and I. Morano. 2009. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ. Res. 105: 326-334.
  19. Cao, H., M. Sekiya, M. E. Ertunc, M. F. Burak, J. R. Mayers, A. White, K. Inouye, L. M. Rickey, B. C. Ercal, M. Furuhashi, G. Tuncman, and G. S. Hotamisligil. 2013. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab. 17: 768-778.
  20. Kralisch, S., N. Kloting, T. Ebert, M. Kern, A. Hoffmann, K. Krause, B. Jessnitzer, U. Lossner, I. Sommerer, M. Stumvoll, and M. Fasshauer. 2015. Circulating adipocyte fatty acid-binding protein induces insulin resistance in mice in vivo. Obesity. (Silver.Spring) 23: 1007-1013.
  21. Kamijo, A., T. Sugaya, A. Hikawa, M. Yamanouchi, Y. Hirata, T. Ishimitsu, A. Numabe, M. Takagi, H. Hayakawa, F. Tabei, T. Sugimoto, N. Mise, M. Omata, and K. Kimura. 2006. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol. Cell Biochem. 284: 175-182.
  22. Yamamoto, T., E. Noiri, Y. Ono, K. Doi, K. Negishi, A. Kamijo, K. Kimura, T. Fujita, T. Kinukawa, H. Taniguchi, K. Nakamura, M. Goto, N. Shinozaki, S. Ohshima, and T. Sugaya. 2007. Renal L-type fatty acid--binding protein in acute ischemic injury. J. Am. Soc. Nephrol. 18: 2894-2902.
  23. Matsui, K., A. Kamijo-Ikemori, N. Imai, T. Sugaya, T. Yasuda, S. Tatsunami, T. Toyama, M. Shimizu, K. Furuichi, T. Wada, Y. Shibagaki, and K. Kimura. 2016. Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Clin. Exp. Nephrol. 20: 195-203.
  24. Lachmann, R. A., S. Werchan, C. Schachtrup, J. J. Haitsma, F. Spener, and B. Lachmann. 2006. Liver-type fatty acid binding protein in serum and broncho-alveolar lavage in a model of acute respiratory failure because of surfactant depletion--a possible marker for lung damage? Clin. Physiol. Funct. Imaging 26: 371-375.
  25. Kawai, A., M. Kusaka, F. Kitagawa, J. Ishii, N. Fukami, T. Maruyama, H. Sasaki, R. Shiroki, H. Kurahashi, and K. Hoshinaga. 2014. Serum liver-type fatty acid-binding protein predicts recovery of graft function after kidney transplantation from donors after cardiac death. Clin. Transplant. 28: 749-754.
  26. Akbal, E., E. Kocak, O. Akyurek, S. Koklu, H. Batgi, and M. Senes. 2016. Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease. Wien. Klin. Wochenschr. 128: 48-52.
  27. Shi, J., Y. Zhang, W. Gu, B. Cui, M. Xu, Q. Yan, W. Wang, G. Ning, and J. Hong. 2012. Serum liver fatty acid binding protein levels correlate positively with obesity and insulin resistance in Chinese young adults. PLoS One 7: e48777.
  28. Ishimura, S., M. Furuhashi, Y. Watanabe, K. Hoshina, T. Fuseya, T. Mita, Y. Okazaki, M. Koyama, M. Tanaka, H. Akasaka, H. Ohnishi, H. Yoshida, S. Saitoh, and T. Miura. 2013. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One 8: e81318.
  29. Kwan, B. C., F. Kronenberg, S. Beddhu, and A. K. Cheung. 2007. Lipoprotein metabolism and lipid management in chronic kidney disease. J. Am. Soc. Nephrol. 18: 1246-1261.
  30. Jin, K., K. Norris, and N. D. Vaziri. 2013. Dysregulation of hepatic fatty acid metabolism in chronic kidney disease. Nephrol. Dial. Transplant. 28: 313-320.
  31. Fuseya, T., M. Furuhashi, S. Yuda, A. Muranaka, M. Kawamukai, T. Mita, S. Ishimura, Y. Watanabe, K. Hoshina, M. Tanaka, K. Ohno, H. Akasaka, H. Ohnishi, H. Yoshida, S. Saitoh, K. Shimamoto, and T. Miura. 2014. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc. Diabetol. 13: 126.
  32. Yeung, D. C., A. Xu, A. W. Tso, W. S. Chow, N. M. Wat, C. H. Fong, S. Tam, P. C. Sham, and K. S. Lam. 2009. Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients. Diabetes Care 32: 132-134.
  33. Girona, J., R. Rosales, N. Plana, P. Saavedra, L. Masana, and J. C. Vallve. 2013. FABP4 induces vascular smooth muscle cell proliferation and migration through a MAPK-dependent pathway. PLoS One 8: e81914.
  34. Yeung, D. C., Y. Wang, A. Xu, S. C. Cheung, N. M. Wat, D. Y. Fong, C. H. Fong, M. T. Chau, P. C. Sham, and K. S. Lam. 2008. Epidermal fatty-acid-binding protein: a new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosis. Eur. Heart J. 29: 2156-2163.
  35. Bagheri, R., A. N. Qasim, N. N. Mehta, K. Terembula, S. Kapoor, S. Braunstein, M. Schutta, N. Iqbal, M. Lehrke, and M. P. Reilly. 2010. Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am. J. Cardiol. 106: 1118-1123.
  36. Bowen, R. A., and A. T. Remaley. 2014. Interferences from blood collection tube components on clinical chemistry assays. Biochem. Med. (Zagreb.) 24: 31-44.
  37. Brunialti, M. K., E. G. Kallas, M. Freudenberg, C. Galanos, and R. Salomao. 2002. Influence of EDTA and heparin on lipopolysaccharide binding and cell activation, evaluated at single-cell level in whole blood. Cytometry 50: 14-18.
  38. Duvigneau, J. C., W. Sipos, R. T. Hartl, M. Bayer, R. Moldzio, L. Stevenson, B. Adair, and M. Gemeiner. 2007. Heparin and EDTA as anticoagulant differentially affect cytokine mRNA level of cultured porcine blood cells. J. Immunol. Methods 324: 38-47.
  39. Freitas, M., G. Porto, J. L. Lima, and E. Fernandes. 2008. Isolation and activation of human neutrophils in vitro. The importance of the anticoagulant used during blood collection. Clin. Biochem. 41: 570-575.
  40. Iwamoto, M., T. Miyoshi, M. Doi, K. Takeda, M. Kajiya, K. Nosaka, R. Nakayama, S. Hirohata, S. Usui, S. Kusachi, K. Sakane, K. Nakamura, and H. Ito. 2012. Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris. Cardiovasc. Diabetol. 11: 26.
  41. Furuhashi, M., N. Ura, K. Hasegawa, H. Yoshida, K. Tsuchihashi, T. Nakata, and K. Shimamoto. 2003. Serum ratio of heart-type fatty acid-binding protein to myoglobin. A novel marker of cardiac damage and volume overload in hemodialysis patients. Nephron Clin. Pract. 93: C69-C74.
  42. Furuhashi, M., N. Ura, K. Hasegawa, K. Tsuchihashi, T. Nakata, and K. Shimamoto. 2004. Utility of serum ratio of heart-type fatty acid-binding protein to myoglobin for cardiac damage regardless of renal dysfunction. Circ. J. 68: 656-659.
  43. Sommer, G., M. Ziegelmeier, A. Bachmann, S. Kralisch, U. Lossner, J. Kratzsch, M. Bluher, M. Stumvoll, and M. Fasshauer. 2008. Serum levels of adipocyte fatty acid-binding protein (AFABP) are increased in chronic haemodialysis (CD). Clin. Endocrinol. (Oxf) 69: 901-905.
  44. Furuhashi, M., S. Ishimura, H. Ota, M. Hayashi, T. Nishitani, M. Tanaka, H. Yoshida, K. Shimamoto, G. S. Hotamisligil, and T. Miura. 2011. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One 6: e27356.
  45. Mori, Y., T. Hirano, M. Nagashima, Y. Shiraishi, T. Fukui, and M. Adachi. 2007. Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure. Metabolism 56: 1714-1718.
  46. Staels, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J. C. Fruchart. 1998. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093.